Want to see JP:4880 full AI Analyst Report?
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥294.00 - ¥736.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)77.65K
Market Cap
¥6.19B
Enterprise Value¥1.41B
Total Cash (Recent Filing)¥4.71B
Total Debt (Recent Filing)¥56.72M
Price to Earnings (P/E)87.6
Beta0.89
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.24%
Share Statistics
EPS (TTM)0.53
Shares Outstanding19,847,778
10 Day Avg. Volume73,510
30 Day Avg. Volume77,646
Financial Highlights & Ratios
PEG Ratio-9.79
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5
Revenue Forecast (FY)¥3.70B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal leverage and a conservative balance sheet materially reduce refinancing and solvency risk for a biotech firm. This durability supports multi-year R&D and commercialization efforts, preserves strategic optionality, and increases resilience to industry funding cycles and revenue volatility.
Consistent Positive Cash GenerationSustained positive operating and free cash flow provides an internal funding source for operations, R&D and select investments without relying heavily on external capital. Over the medium term this supports execution and reduces dilution risk even if cash generation is somewhat volatile.
2025 Revenue ReboundA clear revenue rebound in 2025 demonstrates the company can regain top-line momentum after a dip, indicating underlying market demand or successful commercial initiatives. Coupled with a strong balance sheet and cash generation, this rebound creates a basis for durable recovery of scale.
Bears Say
Sharp Profitability DeteriorationA collapse from double-digit to near-break-even net margins meaningfully reduces return on equity and internal funding capacity. If sustained, the decline weakens the company's ability to finance growth, impairs shareholder returns, and increases sensitivity to revenue setbacks or cost shocks.
Volatile And Weakening Cash QualityFalling and volatile free cash flow and weaker operating cash flow in 2025 signal deteriorating cash quality. This raises the probability of future external funding, cost cuts, or slower program investment, undermining the long-term stability that a biotech needs for multi-year development cycles.
Inconsistent Revenue And Compressed MarginsIrregular top-line performance plus margin compression suggests weak operating leverage or rising operating costs. Over months-to-years this pattern can limit scalability, make earnings less predictable, and indicate structural issues in pricing, cost control, or product mix that require management remediation.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥294.00 and its highest was ¥736.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥6.19B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Sep 10, 2026 which is in 70 days.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Jun 10, 2026. The company reported ¥1.89 earnings per share for the quarter, beating the consensus estimate of N/A by ¥1.89.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.24%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,847,778 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of ¥1.89 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.631%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―